Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12610000496011
Ethics application status
Approved
Date submitted
15/06/2010
Date registered
16/06/2010
Date last updated
16/06/2010
Type of registration
Prospectively registered

Titles & IDs
Public title
A non-invasive way to protect against the stress of surgery for heart disease
Scientific title
The protective effect of remote ischaemic preconditioning in congenital heart disease patients undergoing cardiopulmonary bypass surgery
Secondary ID [1] 252025 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiopulmonary by-pass surgery-associated ischemia-reperfusion stress in paediatric patients with congenital heart disease. 257569 0
Condition category
Condition code
Cardiovascular 257727 257727 0 0
Diseases of the vasculature and circulation including the lymphatic system
Surgery 257742 257742 0 0
Surgical techniques
Human Genetics and Inherited Disorders 257743 257743 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Remote Ischemic Preconditioning (RIPC) will be instituted by four 5-minute cycles of leg ischemia with intervening 5 minutes of reperfusion immediately following induction of standard anaesthesia in the operating room. A standard WelchAllen blood pressure cuff is placed on the mid-to upper thigh of the leg which is free of intravenous (i.v.)/arterial lines. Inflating the blood pressure cuff to a pressure exceeding the patient’s systolic pressure by 30 mmHg will constrict the site to interrupt local blood flow and thus perfusion of the lower leg (i.e. if systolic pressure is 70mmHg then the cuff will be inflated to 100mmHg). The cuff would be deflated to permit reperfusion. Blood flow interruption and restoration will be monitored by standard pulse-oxymetry. RIPC is performed after the patient has been anesthetised while routine central lines are being placed.
Intervention code [1] 256663 0
Treatment: Other
Comparator / control treatment
Control (Placebo) patients will have sham placement of cuff without inflation.
Control group
Placebo

Outcomes
Primary outcome [1] 258618 0
The identification of whether the molecular signalling response (proteome and intracellular signal transduction) in blood (plasma and lymphocyte mitochondria) and cardiac mitochondria (resected tissue) that normally occurs in patients undergoing congenital heart surgery with cardiopulmonary by-pass support is altered by RIPC-treatment (highly regulated, non-invasively-induced, localised leg ischaemia (5min) and reperfusion (5min) for 4 cycles) before surgery.
Timepoint [1] 258618 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours . Myocardial resected tissue, intraoperatively.
Secondary outcome [1] 264551 0
The total doses of inotropic, chronotropic, and afterload reducing agents.
Timepoint [1] 264551 0
Post-operatively at 3, 6, 12, 24 hours .
Secondary outcome [2] 264552 0
Arterial blood gases measured from blood samples by blood gas machine.
Timepoint [2] 264552 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours .
Secondary outcome [3] 264553 0
Mean systemic arterial, and right atrial pressures via in-line catheters and pressure transducers.
Timepoint [3] 264553 0
3, 6, 12, and 24 hours after aortic cross clamp release.
Secondary outcome [4] 264554 0
Serum glucose measured by hospital pathology biochemical assay.
Timepoint [4] 264554 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours.
Secondary outcome [5] 264569 0
Post-operative serum electrolytes measured by hospital pathology biochemical assays.
Timepoint [5] 264569 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours
Secondary outcome [6] 264570 0
Post-operative serum arterial lactate measured by hospital pathology biochemical assay.
Timepoint [6] 264570 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours.
Secondary outcome [7] 264571 0
Post-operative blood urea nitrogen measured by hospital pathology biochemical assay.
Timepoint [7] 264571 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours.
Secondary outcome [8] 264572 0
Post-operative creatinine measured by hospital pathology biochemical assay.
Timepoint [8] 264572 0
Blood samples collected at baseline, and post-operatively at 3, 6, 12, 24 hours.
Secondary outcome [9] 264573 0
Post-operative fluid balance (i.e. recorded total volume and type of fluid intake, urine output, and chest tube drainage).
Timepoint [9] 264573 0
Daily from day of operation until discharge from hospital (generally after 10-12 days).
Secondary outcome [10] 264574 0
Ventilator rates and pressures recorded for estimates of lung function and compliance.
Timepoint [10] 264574 0
From day of operation until extubation of ventilation.
Secondary outcome [11] 264575 0
Post-operative total hours of mechanical respirator ventilation required.
Timepoint [11] 264575 0
The tally of hours from day of operation until extubation of ventilation.
Secondary outcome [12] 264576 0
The number of days in the cardiac intensive care unit and the hospital are recorded.
Timepoint [12] 264576 0
Daily from day of operation until discharge from hospital (generally after 10-12 days).
Secondary outcome [13] 264577 0
The total number of days in hospital.
Timepoint [13] 264577 0
Daily from day of operation until discharge from hospital (generally after 10-12 days).

Eligibility
Key inclusion criteria
Patients with tetralogy of Fallot having surgery for the first time.
Minimum age
1 Months
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients with chromosomal defects, associated congenital lung malformations and haematological disorders

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The implementer of the RIPC or Sham control/placebo treatment protocols will open one sealed envelope in numerical order immediately prior to placement of the blood pressure cuff and they will apply the RIPC treatment or sham control protocol accordingly.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Random allocation is made in blocks in order to keep the sizes of the 2 treatment groups similar. Due to the expected relative uniformity of condition in the patient group and the small number of subjects the design will not be stratified. The randomisation will be performed in secret by a member from Heart Research (not involved in working for the trial) using SPSS statistical software generated randomisation and will place each designation sequentially in numbered envelopes 1 to 40, for patient 1 to 40 and the envelopes will be signed and sealed.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
5/07/2010
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
40
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 257135 0
Government body
Name [1] 257135 0
National Health and Medical Research Council (NHMRC)
Country [1] 257135 0
Australia
Primary sponsor type
Individual
Name
Professor Igor Konstantinov
Address
Department of Cardiac Surgery
Royal Children's Hospital
Flemington Road, Parkville, VIC 3052
Country
Australia
Secondary sponsor category [1] 256392 0
Individual
Name [1] 256392 0
Dr Michael Cheung
Address [1] 256392 0
Department of Cardiology
Royal Children's Hospital
Flemington Road, Parkville, VIC 3052
Country [1] 256392 0
Australia
Secondary sponsor category [2] 256393 0
Individual
Name [2] 256393 0
Dr Salvatore Pepe
Address [2] 256393 0
Heart Research,
Murdoch Children's Research Institute
Royal Children's Hospital
Flemington Road, Parkville, VIC 3052
Country [2] 256393 0
Australia
Secondary sponsor category [3] 256394 0
Individual
Name [3] 256394 0
Dr Vera Ignjatovic
Address [3] 256394 0
Haemotology Research,
Murdoch Children's Research Institute
Royal Children's Hospital
Flemington Road, Parkville, VIC 3052
Country [3] 256394 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 259173 0
Royal Children's Hospital Human Ethics Committee
Ethics committee address [1] 259173 0
Royal Children's Hospital
Flemington Road
Parkville, VIC 3052
Ethics committee country [1] 259173 0
Australia
Date submitted for ethics approval [1] 259173 0
Approval date [1] 259173 0
26/03/2010
Ethics approval number [1] 259173 0
29133

Summary
Brief summary
Lay Summary:
Support of the blood circulation during heart surgery using the heart-lung bypass machine is inevitably associated with organ damage and associated reduced function. This is due to reduced blood flow (ischemia), the effects of restoration of flow (reperfusion injury) and the subsequent inflammation that is caused. The body has its own way of protecting itself against reduced blood flow and oxygen by a mechanism known as preconditioning. In essence, brief periods of mild ischemia are protective against a subsequent more severe episode of ischemia. These periods of mild ischemia can be of the organ itself or of another organ in the body. For example ischemia of the leg can protect the heart against ischemia, so called “remote preconditioning”. We have shown in animal and human models that remote preconditioning using a tourniquet (or blood pressure cuff) placed around a thigh for brief periods (similar in duration to when taking blood samples from children) reduces the amount of injury to heart muscle by 50% and also leads to improved heart and lung function. We have shown that remote preconditioning in a similar way protects the organs of a heterogeneous group of children undergoing cardiac surgery, resulting in better function of the heart and lungs and also a reduction of the inflammatory response to the heart-lung machine. This could potentially reduce the problems in looking after children after surgery and also reduce the amount of time spent in the intensive care unit.
We will study paediatric patients undergoing heart surgery inorder to identify key protein and metabolic changes that occur within this 'heart-protection' protocol. All interventions will be performed during the period of routine general anaesthesia at the time of surgical repair. We will study the degree of organ injury induced by heart-lung bypass using standard intensive care parameters and equipment for measuring lung function. The degree of plasma and blood cell metabolic function will be assessed by laboratory tests. Blood samples will be taken from indwelling catheters routinely placed at the time of surgery and not require additional venepuncture. Measurements will be made prior to surgery and also at set time intervals in the first 24 hours postoperatively to determine the evolution of effects.

Primary Objective:
Does remote ischemic preconditioning (RIPC) modify the global plasma proteomic and mitochondrial response in patients undergoing congenital heart surgery?

Hypothesis:
RIPC induces significant changes to global proteomic response in plasma and the metabolic function in heart muscle and lymphocyte mitochondria of patients undergoing congenital heart surgery.

Aims:
To assess in blood plasma and lymphocyte/myocardial mitochondria the impact of RIPC on the global proteomic and mitochondrial metabolic function response to heart surgery with cardiopulmonary bypass support.

Secondary Objectives:
Does RIPC modify clinical markers of injury and cardiopulmonary function post-Cardiopulmonary bypass in patients undergoing congenital heart surgery?

Hypothesis:
Remote IPC reduces post-cardiopulmonary bypass release of markers of cellular injury and permits recovery of cardiac pump function with less complication including inotrope requirement in patients undergoing congenital heart surgery.

Aims:
To assess the impact of remote IPC on lactate release, inotrope requirement, and standard clinical cardiopulmonary assessments in response to heart surgery with cardiopulmonary bypass support.

This small randomised, blinded, surgical trial of preoperative therapy with highly regulated, brief, non-invasively-induced, localised leg ischaemia and reperfusion, will test for the capacity to invoke remote ischemic preconditioning-related molecular signalling (proteomic and metabolic) changes. The study will recruit 40 paediatric tetralogy of patients to RIPC treatment or SHAM RIPC (Placebo control) treatment groups and is expected to be completed by the end of March 2012.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 31291 0
Address 31291 0
Country 31291 0
Phone 31291 0
Fax 31291 0
Email 31291 0
Contact person for public queries
Name 14538 0
Professor Igor Konstantinov
Address 14538 0
Department of Cardiac Surgery
Royal Childrens' Hospital
Flemington Road
Parkville, VIC, 3052
Country 14538 0
Australia
Phone 14538 0
+61 3 93455200
Fax 14538 0
+61 3 93456386
Email 14538 0
[email protected]
Contact person for scientific queries
Name 5466 0
Professor Igor Konstantinov
Address 5466 0
Department of Cardiac Surgery
Royal Childrens' Hospital
Flemington Road
Parkville, VIC, 3052
Country 5466 0
Australia
Phone 5466 0
+61 3 93455200
Fax 5466 0
+61 3 93456386
Email 5466 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseRemote Ischemic Preconditioning (RIPC) modifies the plasma proteome in children undergoing repair of tetralogy of fallot: A randomized controlled trial.2015https://dx.doi.org/10.1371/journal.pone.0122778
N.B. These documents automatically identified may not have been verified by the study sponsor.